MENU

Board of Directors

Alnylam’s Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization and strategy to our efforts in developing RNAi therapeutics.

Michael W. Bonney (Chair)

Former Chief Executive Officer and director of Cubist Pharmaceuticals; former Partner of Third Rock Ventures; director of Celgene Corporation, Global Blood Therapeutics, Inc. and Revolution Medicines, Inc.; Trustee of Gulf of Maine Research Institute and TEKLA fund complex, focused on healthcare investing.


Dennis A. Ausiello, M.D.

Director of the Center for Assessment Technology and Continuous Health (CATCH); Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Physician-in-Chief Emeritus at Massachusetts General Hospital; director of Pfizer, Inc. and Seres Therapeutics, Inc.


John K. Clarke

Managing General Partner of Cardinal Partners; founder of Alnylam, Alkermes, Inc. and Cubist Pharmaceuticals, Inc.; Chair of the board of directors of aTyr Pharma, Inc.


Marsha H. Fanucci

Former Chief Financial Officer of Millennium Pharmaceuticals; director of Ironwood Pharmaceuticals, Inc. and Syros Pharmaceuticals, Inc.


John M. Maraganore, Ph.D.

Chief Executive Officer of Alnylam; Chair of the board of directors of Agios Pharmaceuticals, Inc.; director of bluebird bio, Inc.


Steven M. Paul, M.D.

Chief Executive Officer, President and director of Voyager Therapeutics, Inc.; Venture Partner at Third Rock Ventures; co-founder and director of SAGE Therapeutics, Inc.; trustee for the Foundation for the National Institute of Mental Health (NIH); former President of the Lilly Research Laboratories of Eli Lilly; Company and former Scientific Director of the National Institute of Mental Health.


David E.I. Pyott

Former Chair and Chief Executive Officer of Allergan; Lead Director of Avery Dennison Corporation; member of the Supervisory Board of Royal Philips in the Netherlands; director of BioMarin Pharmaceutical, Inc.


Paul R. Schimmel, Ph.D.

Ernest and Jean Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute; founder of Alnylam; member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Inventors and the Institute of Medicine; co-founder of Cubist, Alkermes and Repligen; co-founder and director of aTyr Pharma, Inc.


Amy W. Schulman

Co-founder, Chief Executive Officer and director of Lyndra, Inc.; Executive Chair of SQZ Biotech; Venture Partner at Polaris Partners; Former Executive Vice President and General Counsel of Pfizer Inc.; served as the Business Unit Lead for Pfizer’s Consumer Healthcare and Nutrition businesses; senior lecturer at Harvard Business School; director of Ironwood Pharmaceuticals, Inc. and Blue Buffalo Pet Products, Inc.


Phillip A. Sharp, Ph.D.

Institute Professor at The Koch Institute for Integrative Cancer Research, MIT; founding director of McGovern Institute for Brain Research, MIT; Nobel Laureate; founder of Alnylam; co-founder and former director of Biogen, Inc.; member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences; director of Syros Pharmaceuticals, Inc.


Kevin P. Starr, Partner

Third Rock Ventures partner; former Chief Operating Officer and Chief Financial Officer of Millennium Pharmaceuticals, Inc.; director of MyoKardia, Inc. and SAGE Therapeutics, Inc.